BVF Inc. IL increased its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 7.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,585,677 shares of the company’s stock after purchasing an additional 115,343 shares during the quarter. BVF Inc. IL owned about 3.79% of Janux Therapeutics worth $19,187,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Rhumbline Advisers boosted its stake in Janux Therapeutics by 46.9% in the first quarter. Rhumbline Advisers now owns 16,216 shares of the company’s stock valued at $233,000 after acquiring an additional 5,179 shares during the last quarter. California State Teachers Retirement System boosted its stake in Janux Therapeutics by 153.0% in the first quarter. California State Teachers Retirement System now owns 17,331 shares of the company’s stock valued at $210,000 after acquiring an additional 10,480 shares during the last quarter. Balyasny Asset Management LLC bought a new position in Janux Therapeutics in the third quarter valued at approximately $165,000. HRT Financial LP bought a new position in Janux Therapeutics in the fourth quarter valued at approximately $161,000. Finally, MetLife Investment Management LLC boosted its stake in Janux Therapeutics by 100.2% in the first quarter. MetLife Investment Management LLC now owns 10,614 shares of the company’s stock valued at $152,000 after acquiring an additional 5,312 shares during the last quarter. 75.39% of the stock is owned by institutional investors.
Janux Therapeutics Stock Up 5.4 %
Shares of NASDAQ:JANX opened at $10.73 on Tuesday. Janux Therapeutics, Inc. has a 12 month low of $10.09 and a 12 month high of $23.64. The company’s fifty day simple moving average is $12.00 and its 200 day simple moving average is $12.96. The firm has a market cap of $494.65 million, a price-to-earnings ratio of -6.58 and a beta of 1.57.
Insider Buying and Selling
In related news, Director Ra Capital Management, L.P. acquired 495,008 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The shares were acquired at an average cost of $12.46 per share, for a total transaction of $6,167,799.68. Following the completion of the acquisition, the director now directly owns 8,117,246 shares in the company, valued at approximately $101,140,885.16. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 35.40% of the stock is currently owned by company insiders.
Analyst Ratings Changes
A number of brokerages have issued reports on JANX. Wedbush reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of Janux Therapeutics in a research note on Thursday, August 10th. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Janux Therapeutics in a research report on Wednesday, August 9th.
View Our Latest Research Report on JANX
About Janux Therapeutics
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Read More
- Five stocks we like better than Janux Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- An Electrifying New Upgrade for Tesla Leads the Market Higher
- Energy and Oil Stocks Explained
- Oil Jumps, 2 Plastic Stocks About To Become Value Plays
- Best Stocks Under $10.00
- The Top 5 Analysts Calls in September
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
